ONCOLOGY NURSING CLINICAL
HANDBOOK
A Comprehensive Clinical Reference Manual for Advanced Practice
& Staff Oncology Nurses
Covering Cancer Pathophysiology, Antineoplastic Therapeutics,
Immunotherapy, Oncologic Emergencies, Symptom Management, and
Evidence-Based Patient Care Protocols.
Prepared by Oncology Nursing Clinical Educators
Published 2026 | Comprehensive Edition
Comprehensive Oncology Nursing Clinical Handbook Page 1
,Table of Contents
• Module 1: Fundamentals of Cancer Biology and Pathophysiology
• Module 2: Antineoplastic Pharmacotherapy and Safe Administration
• Module 3: Immunotherapy, Targeted Therapy, and Precision Oncology
• Module 4: Oncologic Emergencies
• Module 5: Symptom Management and Palliative Care
Module 1: Fundamentals of Cancer Biology and
Pathophysiology (Part 1)
Carcinogenesis and Cellular Transformation
Cancer is characterized by uncontrolled cellular proliferation and evasion of apoptosis. Normal cells
strictly regulate growth through proto-oncogenes and tumor suppressor genes. When proto-oncogenes
undergo gain-of-function mutations, they become oncogenes, driving aberrant cell signaling. Conversely,
loss-of-function mutations in tumor suppressor genes (e.g., TP53, RB1) abolish cellular brake mechanisms
[1].
The hallmarks of cancer encompass ten key capabilities acquired during tumor development: sustaining
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality,
inducing angiogenesis, activating invasion and metastasis, reprogramming energy metabolism, evading
immune destruction, genome instability, and tumor-promoting inflammation [2].
Tumor Microenvironment and Angiogenesis
The tumor microenvironment (TME) consists of cancer cells, tumor-associated fibroblasts (TAFs), immune
cells, extracellular matrix (ECM), and blood vessels. Vascular Endothelial Growth Factor (VEGF) plays a
central role in tumor angiogenesis. As the tumor mass expands beyond 1-2 mm, hypoxia induces Hypoxia-
Inducible Factor 1-alpha (HIF-1α), triggering sprouting angiogenesis to supply oxygen and nutrients [3].
Metastatic Cascade
Metastasis involves a complex series of steps: local invasion through the basement membrane,
intravasation into circulatory or lymphatic vessels, survival in transit, extravasation at distant sites, and
Comprehensive Oncology Nursing Clinical Handbook Page 2
,colonization. Epithelial-to-Mesenchymal Transition (EMT) is a critical phenotypic transformation allowing
epithelial cancer cells to acquire migratory and invasive properties [4].
References & Footnotes:
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Weinberg RA. The Biology of Cancer. 2nd ed. Garland Science; 2013.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
4. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559-1564.
Module 2: Antineoplastic Pharmacotherapy and Safe
Administration (Part 1)
Classification of Chemotherapeutic Agents
Antineoplastic therapies are classified by mechanism of action and cell-cycle specificity:
• Alkylating Agents: (e.g., Cyclophosphamide, Cisplatin) Cause DNA cross-linking, inhibiting replication.
Cell-cycle non-specific.
• Antimetabolites: (e.g., 5-Fluorouracil, Methotrexate) Substitute for normal metabolites during S-phase
DNA synthesis.
• Antitumor Antibiotics: (e.g., Doxorubicin) Intercalate DNA and inhibit Topoisomerase II. Risk of
cumulative cardiotoxicity.
• Mitotic Inhibitors: (e.g., Paclitaxel, Vincristine) Disrupt microtubule dynamics during M-phase.
Safe Handling and Extravasation Management
Chemotherapeutic agents are hazardous drugs requiring specialized Personal Protective Equipment (PPE)
including chemotherapy-tested gloves, non-linting gowns, and closed-system transfer devices (CSTDs) per
USP <800> standards [5].
Extravasation Management:
• Vesicants: Agents capable of severe tissue necrosis (e.g., Anthracyclines, Vinca Alkaloids).
• Interventions: Immediately stop infusion, aspirate residual drug, do not flush line. Apply cold
compresses for anthracyclines (or warm compresses for Vinca alkaloids), and administer specific
antidotes such as Dexrazoxane for anthracycline extravasation [6].
References & Footnotes:
5. USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings. USP; 2020.
6. Polovich M, Olsen M, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 5th ed. Oncology
Nursing Society; 2018.
Comprehensive Oncology Nursing Clinical Handbook Page 3
, Module 3: Immunotherapy, Targeted Therapy, and Precision
Oncology (Part 1)
Immune Checkpoint Inhibitors (ICIs)
Immune checkpoint inhibitors target regulatory pathways that tumors exploit to escape T-cell recognition.
Key targets include Programmed Death-1 (PD-1), PD-L1, and Cytotoxic T-Lymphocyte-Associated Protein 4
(CTLA-4). Agents such as Pembrolizumab, Nivolumab, and Ipilimumab activate antitumor immune
responses [7].
Immune-Related Adverse Events (irAEs): ICIs can trigger autoimmune reactions affecting any organ
system. Common irAEs include pneumonitis, colitis, hepatitis, thyroiditis, and dermatitis. High-dose
systemic corticosteroids (e.g., Prednisone 1-2 mg/kg/day) are the primary management strategy for Grade
2+ toxicities.
Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy involves genetically engineering patient T-cells to express synthetic receptors targeting
specific tumor antigens (e.g., CD19 in B-cell malignancies). Major toxicities include Cytokine Release
Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) [8].
Treatment for severe CRS involves Tocilizumab (IL-6 receptor antagonist) and supportive care.
References & Footnotes:
7. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
8. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol.
2018;15(1):47-62.
Module 4: Oncologic Emergencies (Part 1)
Neutropenic Fever and Sepsis
Neutropenic fever is defined as a single oral temperature ≥ 38.3°C (101.0°F) or ≥ 38.0°C (100.4°F) sustained
over 1 hour in a patient with an Absolute Neutrophil Count (ANC) < 500 cells/mcL (or expected to fall < 500
cells/mcL).
Formula for ANC calculation:
ANC = WBC × (% Neutrophils + % Bands) / 100
Comprehensive Oncology Nursing Clinical Handbook Page 4
HANDBOOK
A Comprehensive Clinical Reference Manual for Advanced Practice
& Staff Oncology Nurses
Covering Cancer Pathophysiology, Antineoplastic Therapeutics,
Immunotherapy, Oncologic Emergencies, Symptom Management, and
Evidence-Based Patient Care Protocols.
Prepared by Oncology Nursing Clinical Educators
Published 2026 | Comprehensive Edition
Comprehensive Oncology Nursing Clinical Handbook Page 1
,Table of Contents
• Module 1: Fundamentals of Cancer Biology and Pathophysiology
• Module 2: Antineoplastic Pharmacotherapy and Safe Administration
• Module 3: Immunotherapy, Targeted Therapy, and Precision Oncology
• Module 4: Oncologic Emergencies
• Module 5: Symptom Management and Palliative Care
Module 1: Fundamentals of Cancer Biology and
Pathophysiology (Part 1)
Carcinogenesis and Cellular Transformation
Cancer is characterized by uncontrolled cellular proliferation and evasion of apoptosis. Normal cells
strictly regulate growth through proto-oncogenes and tumor suppressor genes. When proto-oncogenes
undergo gain-of-function mutations, they become oncogenes, driving aberrant cell signaling. Conversely,
loss-of-function mutations in tumor suppressor genes (e.g., TP53, RB1) abolish cellular brake mechanisms
[1].
The hallmarks of cancer encompass ten key capabilities acquired during tumor development: sustaining
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality,
inducing angiogenesis, activating invasion and metastasis, reprogramming energy metabolism, evading
immune destruction, genome instability, and tumor-promoting inflammation [2].
Tumor Microenvironment and Angiogenesis
The tumor microenvironment (TME) consists of cancer cells, tumor-associated fibroblasts (TAFs), immune
cells, extracellular matrix (ECM), and blood vessels. Vascular Endothelial Growth Factor (VEGF) plays a
central role in tumor angiogenesis. As the tumor mass expands beyond 1-2 mm, hypoxia induces Hypoxia-
Inducible Factor 1-alpha (HIF-1α), triggering sprouting angiogenesis to supply oxygen and nutrients [3].
Metastatic Cascade
Metastasis involves a complex series of steps: local invasion through the basement membrane,
intravasation into circulatory or lymphatic vessels, survival in transit, extravasation at distant sites, and
Comprehensive Oncology Nursing Clinical Handbook Page 2
,colonization. Epithelial-to-Mesenchymal Transition (EMT) is a critical phenotypic transformation allowing
epithelial cancer cells to acquire migratory and invasive properties [4].
References & Footnotes:
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Weinberg RA. The Biology of Cancer. 2nd ed. Garland Science; 2013.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
4. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559-1564.
Module 2: Antineoplastic Pharmacotherapy and Safe
Administration (Part 1)
Classification of Chemotherapeutic Agents
Antineoplastic therapies are classified by mechanism of action and cell-cycle specificity:
• Alkylating Agents: (e.g., Cyclophosphamide, Cisplatin) Cause DNA cross-linking, inhibiting replication.
Cell-cycle non-specific.
• Antimetabolites: (e.g., 5-Fluorouracil, Methotrexate) Substitute for normal metabolites during S-phase
DNA synthesis.
• Antitumor Antibiotics: (e.g., Doxorubicin) Intercalate DNA and inhibit Topoisomerase II. Risk of
cumulative cardiotoxicity.
• Mitotic Inhibitors: (e.g., Paclitaxel, Vincristine) Disrupt microtubule dynamics during M-phase.
Safe Handling and Extravasation Management
Chemotherapeutic agents are hazardous drugs requiring specialized Personal Protective Equipment (PPE)
including chemotherapy-tested gloves, non-linting gowns, and closed-system transfer devices (CSTDs) per
USP <800> standards [5].
Extravasation Management:
• Vesicants: Agents capable of severe tissue necrosis (e.g., Anthracyclines, Vinca Alkaloids).
• Interventions: Immediately stop infusion, aspirate residual drug, do not flush line. Apply cold
compresses for anthracyclines (or warm compresses for Vinca alkaloids), and administer specific
antidotes such as Dexrazoxane for anthracycline extravasation [6].
References & Footnotes:
5. USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings. USP; 2020.
6. Polovich M, Olsen M, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 5th ed. Oncology
Nursing Society; 2018.
Comprehensive Oncology Nursing Clinical Handbook Page 3
, Module 3: Immunotherapy, Targeted Therapy, and Precision
Oncology (Part 1)
Immune Checkpoint Inhibitors (ICIs)
Immune checkpoint inhibitors target regulatory pathways that tumors exploit to escape T-cell recognition.
Key targets include Programmed Death-1 (PD-1), PD-L1, and Cytotoxic T-Lymphocyte-Associated Protein 4
(CTLA-4). Agents such as Pembrolizumab, Nivolumab, and Ipilimumab activate antitumor immune
responses [7].
Immune-Related Adverse Events (irAEs): ICIs can trigger autoimmune reactions affecting any organ
system. Common irAEs include pneumonitis, colitis, hepatitis, thyroiditis, and dermatitis. High-dose
systemic corticosteroids (e.g., Prednisone 1-2 mg/kg/day) are the primary management strategy for Grade
2+ toxicities.
Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy involves genetically engineering patient T-cells to express synthetic receptors targeting
specific tumor antigens (e.g., CD19 in B-cell malignancies). Major toxicities include Cytokine Release
Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) [8].
Treatment for severe CRS involves Tocilizumab (IL-6 receptor antagonist) and supportive care.
References & Footnotes:
7. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
8. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol.
2018;15(1):47-62.
Module 4: Oncologic Emergencies (Part 1)
Neutropenic Fever and Sepsis
Neutropenic fever is defined as a single oral temperature ≥ 38.3°C (101.0°F) or ≥ 38.0°C (100.4°F) sustained
over 1 hour in a patient with an Absolute Neutrophil Count (ANC) < 500 cells/mcL (or expected to fall < 500
cells/mcL).
Formula for ANC calculation:
ANC = WBC × (% Neutrophils + % Bands) / 100
Comprehensive Oncology Nursing Clinical Handbook Page 4
